Company: MLTX
Filing Date: 2025-08-05
Form Type: 10-Q
Source: 0001821586-25-000018
Chunk: 106

Company: MoonLake Immunotherapeutics
Filing Date: 2025-08-05
Form: 10-Q
Item: Part I, Item 8
Chunk 106
---
 ESPP grants will vest 25% on each anniversary of the grant date. In the event of a termination of contractual relationship between the Company and the entitled employee, the awards can be deemed forfeited by MoonLake AG if certain conditions are met. Awards feature an accelerated vesting condition linked to a “Change of Control”, defined as any transfer of shares that results in the proposed acquirer holding more than 50% of the then issued share capital of MoonLake AG or the Company, as the case may be, where all the outstanding awards (whether currently outstanding or granted in the future) will be deemed fully vested.ESPPNumber of SharesWeighted-Average Grant Date Fair ValueAwards unvested as of January 1, 2025319,76910.00Awards vested for the six months ended June 30, 2025(146,934)10.00Awards unvested as of June 30, 2025172,83510.00As of June 30, 2025, MoonLake AG had $1.6 million of total unrecognized compensation expense related to the ESPP that will be recognized over the weighted average period of 0.55 years.Employee Stock Option Plan (ESOP) 2021-2025 - MoonLake AGThe ESOP grants vested 25% on each anniversary of the grant date. In the event of a termination of the contractual relationship between the Company and the entitled employee, options could have been deemed forfeited by MoonLake AG if certain conditions were met. The awards featured an accelerated vesting condition linked to a “Change of Control”, defined as any transfer of shares that resulted in the proposed acquirer holding more than 50% of the then issued share capital of MoonLake AG or the Company, as the case may be, where all the outstanding awards (whether currently outstanding or granted in the future) would have been deemed fully vested. 

25

MOONLAKE IMMUNOTHERAPEUTICSNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2025(Unaudited)

ESOPNumber of OptionsWeighted-Average Exercise PriceAggregate Intrinsic Value (in thousands)Weighted-Average Remaining Contractual Term (in years)Awards outstanding as of January 1, 202598,3931.505,1806.73Awards exercised for the six months ended June 30, 2025(93,347)1.30Awards forfeited for